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Abstract: Colistin sulfate (polymixin E) is an antibiotic prescribed with increasing frequency for
severe Gram-negative bacterial infections. As nephrotoxicity is a common side effect, the discovery
of pharmacogenomic markers associated with toxicity would benefit the utility of this drug. Our
objective was to identify genetic markers of colistin cytotoxicity that were also associated with
expression of key proteins using an unbiased, whole genome approach and further evaluate
the functional significance in renal cell lines. To this end, we employed International HapMap
lymphoblastoid cell lines (LCLs) of Yoruban ancestry with known genetic information to perform
a genome-wide association study (GWAS) with cellular sensitivity to colistin. Further association
studies revealed that single nucleotide polymorphisms (SNPs) associated with gene expression and
protein expression were significantly enriched in SNPs associated with cytotoxicity (p ≤ 0.001 for gene
and p = 0.015 for protein expression). The most highly associated SNP, chr18:3417240 (p = 6.49 × 10−8 ),
was nominally a cis-expression quantitative trait locus (eQTL) of the gene TGIF1 (transforming
growth factor β (TGFβ)-induced factor-1; p = 0.021) and was associated with expression of the
protein HOXD10 (homeobox protein D10; p = 7.17 × 10−5 ). To demonstrate functional relevance in a
murine colistin nephrotoxicity model, HOXD10 immunohistochemistry revealed upregulated protein
expression independent of mRNA expression in response to colistin administration. Knockdown
of TGIF1 resulted in decreased protein expression of HOXD10 and increased resistance to colistin
cytotoxicity. Furthermore, knockdown of HOXD10 in renal cells also resulted in increased resistance
to colistin cytotoxicity, supporting the physiological relevance of the initial genomic associations.
Keywords: colistin; lymphoblastoid cell line; nephrotoxicity; TGIF1; HOXD10
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1. Introduction
Colistin (polymixin E) is a cyclic polypeptide antibiotic prescribed to treat resistant Gram-negative
infections [1,2]. In clinical settings, the drug is administered as an anionic prodrug, colistin
methanosulfate, which is subsequently hydrolyzed to the cationic colistin [3]. The major toxicities
of colistin include nephrotoxicity [4] and neurotoxicity [5]. The use of colistin is often limited by
nephrotoxicity, affecting up to 55% of recipients [6–10]. The deleterious consequences of nephrotoxicity
include increased morbidity, mortality, and the development of chronic kidney disease. Clinical
predictors of colistin nephrotoxicity do exist [11,12]; however, no genetic predictors of colistin
nephrotoxicity have been discovered. The utility of the drug would be enhanced by the discovery of
pharmacogenomic markers associated with toxicity that could be used to predict patients requiring
dose reduction, altered dosing intervals, or increased monitoring to prevent nephrotoxicity.
Lymphoblastoid cell lines (LCLs) are a human cell-based model system that has been successfully
utilized to identify genomic markers associated with cellular sensitivity to chemotherapeutics [13–18]
and statins [19,20]. For this purpose, the LCL model from the International HapMap Consortium [21]
has several advantages including publically available genetic information [21], gene expression [22],
and protein expression data [23] to correlate with cytotoxicity (cell growth inhibition following drug
exposure) phenotypes. Furthermore, associations between genetic variants and drug responses in
LCLs have been replicated in patient samples [24–27]. Although tissue-specific patterns of gene and
protein expression exist [28,29], the LCL model of drug-induced cytotoxicity captures components
of the underlying polygenic architecture in non-hematologic toxicities of patients [30]. For example,
single nucleotide polymorphisms (SNPs) associated with capecitabine-induced LCL cytotoxicity were
enriched among SNPs associated with patient phenotypes of hand-foot syndrome [31]. Paclitaxel
cytotoxicity-associated SNPs were likewise enriched among SNPs identified in a clinical trial of
paclitaxel sensory peripheral neuropathy [32]. These successful translations from the LCL model to
patients form the basis of our use of the LCL model to uncover genetic predictors of colistin toxicity.
In this report, we utilize an unbiased, comprehensive approach to identify genetic variants
associated with colistin cytotoxicity that were further evaluated for potential functional significance
through their association with gene expression and protein expression. The most highly associated SNP,
located at chr18:3417240, was associated with colistin cytotoxicity and was a nominal cis-expression
quantitative trait locus (eQTL) of its host gene, TGIF1 (transforming growth factor β (TGFβ)-induced
factor-1), a homeobox gene and negative regulator of TGF-β [33,34]. The SNP was similarly associated
with the expression of the multimeric form of a protein, HOXD10 (homeobox protein D10). To validate
the associations from our population genetic analyses and establish the relevance of these genetic
associations in renal tissue, small interfering RNA (siRNA) knockdowns of TGIF1 and HOXD10 were
undertaken in renal proximal tubular epithelial cells [35], among the cells most susceptible to renal
toxicity [36].
The pharmacogenomic markers identified through these studies reveal important considerations
in the molecular biology and pathogenesis of colistin toxicity and can be evaluated as predictors of
toxicity in future clinical settings.
2. Results
2.1. Colistin-Induced Cytotoxicity in Lymphoblastoid Cell Lines
Lymphoblastoid cell lines derived from individuals within the Yoruban (YRI) YRI1 and YRI3
populations were assessed for sensitivity to colistin. The mean half maximal inhibitory concentration
(IC50 ) for all 68 unrelated cell lines was 176.5 ± 6.6 µM. Phenotypes were generated from the log2 IC50
of each cell line and a histogram of the distribution of these phenotypes is illustrated in Figure S1. These
phenotypes were normally distributed, passing a Kolmogorov–Smirnov normality test (p ≥ 0.05).
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Figure 1. Schematic diagram of experimentation and analyses. Association studies were performed in
Figure 1. Schematic diagram of experimentation and analyses. Association studies were performed
68 Yoruban (YRI) cells using 10 million single nucleotide polymorphisms (SNPs) (imputed), baseline
in 68 Yoruban (YRI) cells using 10 million single nucleotide polymorphisms (SNPs) (imputed),
gene expression measured by RNA sequencing (RNAseq), and baseline protein expression measured
baseline gene expression measured by RNA sequencing (RNAseq), and baseline protein expression
by microwestern and reverse phase protein arrays. Given the pertinence of colistin toxicity to human
measured by microwestern and reverse phase protein arrays. Given the pertinence of colistin
kidney injury, associations were then validated in human renal proximal tubular cells. GWAS:
toxicity to human kidney injury, associations were then validated in human renal proximal tubular
Genome-wide association study; pQTLs: Protein quantitative trait loci.
cells. GWAS: Genome-wide association study; pQTLs: Protein quantitative trait loci.

2.3. Functional Enrichment of Expression Quantitative Trait Loci and Protein Quantitative Trait Loci
To determine whether colistin cytotoxicity dQTLs were enriched in SNPs that were also associated
with gene expression as has been observed for several chemotherapeutics [37], we performed a
permutation analysis with eQTLs defined as those SNPs associated with at least one of 18,227 genes
measured by RNA sequencing (RNAseq) at a threshold of p ≤ 0.0001 [38]. From among the 2711 dQTLs,
1402 SNPs were also eQTLs and were significantly enriched when compared to that expected by
random chance (Figure 2B, empirical p ≤ 0.001).
Using a protein dataset composed of 441 human signaling and transcription factor proteins that
were quantified in these cell lines using a microwestern and/or reverse phase protein array [23,39],
we evaluated for the enrichment of protein quantitative trait loci (pQTLs); genotype correlated to
protein expression at p ≤ 0.0001). Of the 2711 dQTLs, 271 were associated with baseline expression
of 130 unique proteins (Supplementary Table S2). However, mRNA expression significantly affected
expression of many of these protein associations. After correcting for mRNA expression, 104 SNPs
were identified as pQTLs independent of eQTLs. The 104 mRNA-independent pQTLs represent a
significantly enriched functional set of SNPs (Figure 2C, p = 0.015).

Int. J.Sci.
Mol.2017,
Sci. 2017,
18, 661
Int. J. Mol.
18, 661

4 of 214 of 20

Figure 2. Genetic association studies: (A) Manhattan plot of association between SNPs and colistin half
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colistin susceptibility-associated SNPs (p = 0.015). (D) Quantile–quantile (Q–Q) plot representing the
observed associations between baseline protein expression and colistin IC50 . At p ≤ 0.05, 23 proteins
were significantly associated. Solid line indicates a false discovery rate (FDR) of 0.05.
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2.4. Association of Protein Expression with Colistin Cytotoxicity
The direct correlation between baseline protein expression of the 441 proteins and colistin log2
IC50 was then queried. The significance of these associations is provided in a quantile–quantile (Q–Q)
plot with a multiple testing corrected false discovery rate (FDR) of 0.05 (Figure 2D). Fourteen proteins
had observed associations stronger than those expected by chance. At a relaxed p ≤ 0.05, 23 proteins
were associated with colistin cytotoxicity (Table S3).
2.5. Evaluation of the Most Significant Single Nucleotide Polymorphism Associated with Colistin Cytotoxicity
The SNP most significantly associated with colistin cytotoxicity in the 68 cell lines was an
imputed intronic SNP located on chromosome 18 at base pair 3,417,240 (GRCh38/hg38) in the
gene TGIF1. The genotype of this dQTL, hereby referred to as chr18:3417240, was correlated with
the log2 IC50 for colistin at a level close to the genome-wide significance threshold of 5 × 10−8
(R2 = 0.36, p = 6.49 × 10−8 , Figure 3A). The minor allele (G) frequency was 24.3% in the population
studied and this allele conferred resistance to colistin cytotoxicity. Although the association between
chr18:3417240 and colistin cytotoxicity nearly reached a genome-wide threshold of significance, many
downstream associations with baseline protein and baseline gene expression in LCLs did not approach
Bonferroni-corrected levels of significance. We present these downstream targets to glean insight into
the functional relationship between the SNP and colistin cytotoxicity.
2.6. chr18:3417240 and Homeobox Protein D10 Expression
To better understand how chr18:3417240 might mediate resistance to colistin cytotoxicity, we
examined whether it was also an eQTL or pQTL. In both the genotype-RNAseq expression and
genotype-protein association studies, chr18:3417240 was most strongly associated with expression
of the protein HOXD10. Homeobox protein D10 is encoded by its gene located on chromosome 2.
The monomeric form is 38 kDa in size, but it is well known to form multimers by dimerization,
heterodimerization, or trimerization [40,41]. On the microwestern array, both a 38 kDa HOXD10
isoform and a 75 kDa isoform were found. It is possible that the 75 kDa isoform represents a multimeric
or cross-hybridized form of HOXD10; however, the sensitivity of the microwestern array is insufficient
to discern the exact size and nature of this isoform.
Chr18:3417240 was identified as a trans-pQTL, associated with expression of the 75 kDa form
of the protein HOXD10 (R2 = 0.21, p = 7.17 × 10−5 ). The G allele correlated with higher levels of
75 kDa protein expression on the microwestern array (Figure 3B). Based on the positive correlation of
the G allele with both 75 kDa expression and the log2 IC50 of colistin (from Figure 3A,B), the 75 kDa
expression is predicted to correlate positively with the log2 IC50 of colistin (i.e., greater HOXD10 75 kDa
expression predicts resistance to colistin cytotoxicity). While the directionality of this association
followed predictions, the relationship between 75 kDa protein expression and the log2 IC50 of colistin
failed to reach significance (p = 0.056, Figure 3C).
A second HOXD10 isoform of approximately 38 kDa was also detected on the microwestern
array. This 38 kDa isoform may represent the monomeric form of HOXD10 on the microwestern array.
The genotype of chr18:3417240 was not significantly associated with expression of 38 kDa HOXD10
(Figure 3D). Further, expression of the 38 kDa HOXD10 did not significantly correlate with the log2
IC50 of colistin (p = 0.11, Figure 3E). Although non-significant, both relationships held the opposite
direction of effect to the 75 kDa HOXD10 protein expression (i.e., reduced 38 kDa HOXD10 predicts
resistance to colistin).
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Figure 3. Association studies of chr18:3417240, TGIF1 (transforming growth factor β (TGFβ)-induced
factor-1) and the protein HOXD10 (homeobox protein D10): (A) The SNP chr18:3417240 is associated
with colistin cytotoxicity (log2 IC50 ) at p = 6.47 × 10−8 ; (B) Chr18:3417240 was associated with
expression of HOXD10 (75 kDa isoform) at p = 7.17 × 10−5 ; (C) HOXD10 protein expression (75 kDa)
was not significantly associated with colistin cytotoxicity at p = 0.056; however, the direction of effect for
this result is consistent with A and B; (D) Chr18:3417240 was not associated with expression of HOXD10
(38 kDa isoform) at p = 0.59; (E) HOXD10 protein expression (38 kDa) was not significantly associated
with colistin cytotoxicity at p = 0.11; (F) the homozygous recessive (GG) genotype of chr18:3417240 had
significantly lower TGIF1 gene expression than heterozygous (AG, p = 0.031) or homozygous dominant
(AA, p = 0.021) lymphoblastoid cell lines; (G) TGIF1 gene expression is associated with HOXD10 protein
expression (75 kDa) at p = 0.012 (from Illumina array); and (H) TGIF1 gene expression is associated
with HOXD10 protein expression (38 kDa) at p = 0.016 (from Illumina array). The association between
TGIF1 gene expression and either 75 kDa or 38 kDa HOXD10 protein expression was not significant as
measured by the RNA sequencing platform (see Figure S2).
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We then examined whether HOXD10 baseline gene expression by RNAseq correlated with
genotype, protein expression, or cytotoxicity. Unfortunately, HOXD10 gene expression was only
detected above background thresholds in 3 of 68 cell lines. Thus, no relationship with gene expression
could be established using the RNAseq expression [38]. We entertained the idea that HOXD10 gene
expression was insufficiently captured by RNAseq and examined baseline LCL expression on a second
platform, an Illumina microarray [42]. Although expression measurements were available for 53 of
the LCLs, the dynamic range of expression was small. No significant associations between HOXD10
gene expression and genotype, protein expression, or cytotoxicity were found. Thus, chr18:3417240
appears to be an mRNA-independent pQTL of HOXD10. However, we cannot exclude the possibility
that small, undetectable differences in gene expression mediate the variation in protein expression.
2.7. Transforming Growth Factor β-Induced Factor-1 Gene Expression
Chr18:3417240 genotype was associated with expression of its host gene TGIF1 (Figure 3F). Using
gene expression measured by RNAseq, the homozygous recessive genotype (GG) was associated
with lower expression of TGIF1 as compared to either the homozygous dominant (AA, p = 0.021) or
heterozygous (p = 0.031) genotypes. No significant expression difference was observed between the
AA and AG genotypes.
We then sought to explore the relationship between TGIF1 gene expression with both colistin
cytotoxicity and HOXD10 protein expression. Based on the correlation of the GG genotype with
increased log2 IC50 of colistin, increased 75 kDa HOXD10 expression, and reduced TGIF1 expression
(from Figure 3A,B,F), higher TGIF1 gene expression is predicted to: (i) negatively correlate with the
log2 IC50 of colistin (i.e., knockdown of gene expression would increase cellular sensitivity to colistin);
(ii) negatively correlate with 75 kDa expression of HOXD10; and (iii) positively correlate with 38 kDa
HOXD10 expression. None of these three associations reached statistical significance using expression
data from RNAseq (Figure S2).
To complement the RNAseq expression data, we again examined a second set of expression
data for the same LCLs from the Illumina array platform. Using these expression data, TGIF1 gene
expression did correlate significantly with HOXD10 protein expression (Figure 3G–H). Consistent
with the predictions above, TGIF1 expression negatively correlated with 75 kDa HOXD10 expression
(R2 = 0.123, p = 0.012) and positively with 38 kDa HOXD10 expression (R2 = 0.12, p = 0.016). The
direction of effect for the Illumina array associations was the same as those of the RNAseq associations.
The association between the GG genotype of chr18:3417240 and TGIF1 expression on the Illumina array
persisted (Figure S2, p = 0.05), in accordance with the results from RNAseq. The relationship between
TGIF1 expression and log2 IC50 of colistin remained non-significant on the Illumina platform. These
data support the hypothesis that chr18:3417240 impacts TGIF1 expression and that TGIF1 expression
in turn affects HOXD10 protein isoform expression.
2.8. Homeobox Protein D10 Expression Is Upregulated in the Kidney in Response to Colistin, Independent of Its
Gene Expression
One goal of this investigation was to identify genetic variants in LCLs that predict susceptibility
to colistin-induced nephrotoxicity; however, gene and protein expression patterns vary in different
tissues [28,29]. Variants, genes, and proteins discovered in LCLs may not be associated with colistin
toxicity in the kidney. As a result, we sought to determine whether the HOXD10 protein was expressed
in kidney and whether this expression was affected by colistin administration.
Mice were administered either colistin (16 mg/day) or saline intraperitoneally and sacrificed on
day 3 or 15 as previously described [36]. The dose was approximately twice the upper limit of the
recommended corresponding weight-based human dose and the timing reflected a typical two-week
course of antibiotics. Homeobox protein D10 expression and distribution was assessed in formalin
fixed kidney by immunohistochemistry (IHC; Figure 4A–C). Even before the onset of overt pathologic
kidney injury, HOXD10 protein expression was subtly but significantly upregulated after three days of
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colistin exposure (Figure 4D, 0.368% ± 0.1%) compared with control (0.106% ± 0.03%, p = 0.044), as
determined by the total proportion of stained pixels in a 40× field. HOXD10 was more remarkably
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To understand whether gene expression played a role in the HOXD10 protein expression changes,
we extracted data from an Illumina Mouse WG-6 Expression array performed in control mice and
those receiving colistin for three days (Figure 4E). Transforming growth factor β is known to interact
with Tgif1. Tgfb3 (transforming growth factor β-3) gene expression was significantly upregulated
(1.81 ± 0.058 fold increase, p = 0.016), suggesting this pathway is activated in mice receiving colistin.
Hoxd10 gene expression was not significantly changed (94% ± 0.8% of control, p = 0.699). This may
be consistent with the lack of mRNA and protein expression correlation observed in LCLs; however,
small changes in gene expression at the limits of detection cannot be excluded. Tgif1 gene expression
was not significantly increased (1.16 ± 0.02-fold increase, p = 0.11). Speculation regarding the lack of
significant differential Tgif1 expression after three days of colistin is provided in the discussion. The
murine kidney IHC and array data presented here provided us enough justification to move forward
with the functional validation outlined below. These data will also provide the basis for future gene
knockdown experimentation and pathway interrogation in organisms.
Int. J. Mol. Sci. 2017, 18, 661
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Four conditions were evaluated: siScramble control, siTGIF1, siHOXD10, and siTGIF1 + siHOXD10
(a combined knockdown). siRNA knockdown of TGIF1 reduced its gene expression to 45.1% ± 7.5%
24 h after knockdown compared to the time matched siScramble control (p = 0.018, Figure 6A).
siHOXD10 displayed no significant effect on expression of TGIF1 (1.21 fold increase, p = 0.47). The
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2.11. Small Interfering RNA Knockdown of Transforming Growth Factor β-Induced Factor-1 and Homeobox
Protein D10 Alters Sensitivity to Colistin in Normal Human Proximal Tubular Kidney Cells
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In the population genomic studies described above, HOXD10 protein expression did not
significantly correlate with HOXD10 gene expression. Despite this, we posited that siRNA knockdown
of HOXD10 mRNA might still result in a significant change in HOXD10 protein expression. Based
on the associations in Figure 3G–H, we further hypothesized that TGIF1 knockdown would reduce
monomeric HOXD10 protein expression and increase 75 kDa HOXD10 protein expression.
Homeobox protein D10 was lowly expressed by real-time quantitative polymerse chain reaction
(qRT-PCR) in NHPTK cells with raw threshold cycle (CT ) values in the 30–32 range. By contrast,
TGIF1 CT values were approximately 21–22. Nonetheless, HOXD10 expression was modestly reduced
to 68.7% ± 5.6% of the siScramble control 24 h after knockdown (p = 0.0068). Homeobox protein
D10 expression was reduced to 69.1% ± 9.9% of the control (p = 0.023) after the combined siTGIF1 +
siHOXD10 knockdown. siTGIF1 did not cause a significant reduction in HOXD10 gene expression
(80.8% ± 11.6%, p = 0.18).
Homeobox protein D10 expression of both the 38 kDa and 75 kDa isoforms was assessed by
Western immunoblot for each of the four conditions after siRNA knockdown (n = 5 for each condition).
siHOXD10 resulted in a reduction of its own monomeric protein expression (52.6% ± 8.7% of control,
p = 0.0022) as estimated by densitometry (Figure 6B–D). Despite the lack of HOXD10 gene and protein
expression correlation in the population genomics studies, this finding is consistent with the conclusion
that relatively modest reductions in HOXD10 mRNA can result in reductions in its protein expression.
siTGIF1 + siHOXD10 resulted in a similar reduction in monomeric HOXD10 protein expression
(59.4% ± 0.5% of control, p = 0.0009) as estimated by densitometry. Finally, siTGIF1 knockdown also
resulted in a reduction in monomeric HOXD10 protein expression (70.7% ± 5.9% of control, p = 0.0087)
as estimated by densitometry.
In contrast, the siTGIF1 and siTGIF1 + siHOXD10 conditions showed increased levels of protein
detected by the HOXD10 antibody at 75 kDa (siTGIF1: 3.5 ± 1.4-fold increase, p = 0.044; siTGIF1
+ siHOXD10: 1.5 ± 0.2-fold increase, p = 0.040). siHOXD10 did not significantly increase 75 kDa
HOXD10 (2.2 ± 0.6-fold, p = 0.065). In NHPTK cells, total HOXD10 protein was still reduced in all
conditions because the proportion of the 38 kDa protein far outweighed the 75 kDa protein.
These findings support the population genomics results presented in Figure 3. Expression
of the TGIF1 gene was positively correlated with monomeric HOXD10 protein expression and
negatively correlated with 75 kDa HOXD10 expression. Given the limitations in determining HOXD10
gene expression by RNAseq, Illumina array, and qRT-PCR, it cannot be determined from these
studies whether TGIF1 gene expression changes result in HOXD10 protein changes via downstream
post-translational modifications or by subtle reductions in gene expression.
2.11. Small Interfering RNA Knockdown of Transforming Growth Factor β-Induced Factor-1 and Homeobox
Protein D10 Alters Sensitivity to Colistin in Normal Human Proximal Tubular Kidney Cells
The effect of siRNA knockdown of TGIF1 and HOXD10 mRNA on colistin cytotoxicity was
assessed in NHPTK cells. Based on the population genomic studies presented in Figure 3 and
Figure S2, a higher colistin log2 IC50 (i.e., increased resistance to colistin cytotoxicity) correlated with
the G allele of chr18:3417240. Increased resistance to colistin cytotoxicity is predicted to correlate with:
(i) reduced TGIF1 gene expression; (ii) reduced monomeric HOXD10 expression; and (iii) increased
75 kDa HOXD10 expression. Thus, siRNA knockdown of each condition (siTGIF1, siHOXD10, and
siTGIF1 + siHOXD10) is expected to elicit an increase in resistance to colistin cytotoxicity as compared
to a scrambled siRNA.
siTGIF1 knockdown resulted in an increase in cell survival in response to colistin (Figure 6E).
Although no significant difference was observed at the 50 or 100 µM colistin dose, at higher doses
of 150 µM to 500 µM, NHPTK cells were more resistant to colistin as compared to the dose matched
siScramble. The relative increase (ratio of siTGIF1 to siScramble) for each concentration is provided in
Figure 6E and ranged from a 17.4% to 211.8% increase in relative resistance. The absolute increase in
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resistance was modest but significant, ranging from 4.5% to 9.4% at each concentration of 150 µM or
higher (p ≤ 0.05). Both the absolute and relative resistance increased with increasing doses.
siHOXD10 knockdown also resulted in an increase in cell survival in response to colistin as
compared to the siScramble. Significant but modest increases were observed at each colistin dose.
Compared with siTGIF1, the relative increase in resistance caused by siHOXD10 was more consistent
across each colistin dose, ranging from 4.3% to 33.1% at each dose (p ≤ 0.05). The absolute increase in
resistance ranged from 9.4% at the 100 µM dose down to only 0.8% at the 500 µM dose.
Combined mRNA reduction with siTGIF1 and siHOXD10 resulted in neither a synergistic nor
additive effect; rather, the combined knockdown recapitulated the stronger of the effects from either
siTGIF1 or siHOXD10 at each dose. For example, at lower colistin doses (50–150 µM), the relative and
absolute increases in resistance were similar to siHOXD10 (8.7% to 20.7% relative increase, p ≤ 0.05).
At higher concentrations (250–500 µM), the relative and absolute increases in resistance were similar to
siTGIF1 (86.8% to 189.1% relative increase, p ≤ 0.05).
3. Discussion
In this investigation, the results of a comprehensive GWAS of colistin cytotoxicity are presented.
Colistin cytotoxicity associated SNPs were enriched in eQTLs and mRNA-independent pQTLs. The
data presented in this investigation suggest that chr18:3417240 is a dQTL of colistin, an mRNA
independent pQTL of the protein HOXD10 and nominal cis-eQTL of its host gene TGIF1. After
confirming in vivo kidney expression of HOXD10, these associations were then tested in human renal
proximal tubular cells through siRNA knockdown, supporting the relationship of TGIF1 and HOXD10.
Specifically, the knockdown of TGIF1 led to reduced protein expression of monomeric HOXD10.
Transforming growth factor β-Induced homeobox 1, or TGIF1, is a protein-coding gene important
in the TGF-β signaling axis [33]. In conjunction with Smad, it is a known repressor of TGF-β [34], and
rises in response to elevated levels of the cytokine [44]. The TGIF1 protein binds directly to c-Jun to
assemble with Smad proteins and mediate the transcriptional repression of TGF-β and other genes [45].
In the presented studies, TGIF1 siRNA knockdown resulted in increased cell survival following colistin
exposure. Expression of TGIF1 has been demonstrated to regulate stem cell self-renewal [46] and in
TGIF1 (−/−) knockout mice, loss of expression correlated with higher repopulation of bone marrow
cells [46]. The TGIF1 gene is known to have over 20 splicing variants [47]. Transcript variant expression
levels have been measured in tissues with over- or under-expression of certain variants correlating
with the presence or absence of malignancy. In a study of oral squamous cell carcinomas, transcript
TGIF1-008 was over-expressed and TGIF1-005 under-expressed in malignant tissue [48].
siTGIF1 resulted in reductions in HOXD10 protein expression in our studies. However, siTGIF1
and siHOXD10 had different patterns of cytotoxicity with siTGIF1 resulting in more pronounced
changes at higher colistin doses. By contrast, siHOXD10 resulted in more consistent increases in cell
survival across the dosing range. It is possible that mRNA reduction of TGIF1 resulted in a variety of
downstream effects, including changes in expression of other genes and proteins resulting in both cell
survival and cell death, with the balance shifting to cell survival only under higher concentrations of
colistin. One potential limitation of the siRNA knockdown model is that a pool of siRNA constructs was
used to knockdown all transcripts (as the exons near the 3’ end are conserved across transcript variants).
Future studies should examine the role of transcript variant specific knockdown in cytotoxicity.
Homeobox D10, or HOXD10, is a 38 kDa protein with roles in regulation of the cell cycle and in
the development of the spinal cord and kidney [49–51]. A mutation in HOXD10 has been found to
be a causative variant in Wilm’s tumor (a pediatric renal tumor) [52], further supporting its role in
the kidney’s cell cycle. Homeobox protein D10 is a target of the microRNA miR-7, which suppresses
p21/CDKN1a (Cyclin-dependent kinase inhibitor 1α) activated kinase [53]. Our group’s prior work
has implicated G2/M cell-cycle arrest in the pathogenesis of colistin nephrotoxicity [36]. Thus, the
role of HOXD10 in colistin cytotoxicity is plausible given its renal expression and link to the cell
cycle. Although specific interactions between the TGIF1 gene and Homeobox protein D10 have
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not been previously reported, these interactions are also plausible. Homeobox HOX proteins have
DNA-binding sites, operating as transcription factors downstream of bone morphogenetic protein
(BMP) signaling, part of the TGF-β signaling superfamily [54]. Smad1 and Smad6 interact directly
through T-box 1 (Tbx1) with the HOXD10 protein, repressing its transcriptional activity [51]. Based
on this, TGIF1 and HOXD10 likely interact through the TGF-β/BMP-signaling pathway, potentially
linked by Smad proteins.
Several limitations exist. First, this study identified genes in a lymphoblastoid cell model and
replication in relevant cell types will be required to better elucidate downstream pathways. The
68 unrelated YRI samples are a relatively small sample size for GWAS. The association between
chr18:3417240 and cytotoxicity, at p ≤ 6.49 × 10−8 , failed to reach a genome-wide significance threshold
of p ≤ 5 × 10−8 . This limitation was addressed by the experimentation in NHPTK cells that supports
the associations identified in the population genomics portion of the paper. Another limitation is that
the pQTL association data is based on antibody-based, targeted proteomic array data [39] and the
strength of the corresponding antibodies and methodology (including reducing conditions) used for
quantification. Finally, other limitations include the polygenic nature of cytotoxicity and corresponding
modest effect of any single gene knockdown, the need to overcome tissue specificity of expression,
and the low gene expression of HOXD10 on multiple platforms (RNAseq, Illumina, and qRT-PCR).
Despite these limitations, this work identified two new genes that have not previously been
considered in the pathogenesis of colistin nephrotoxicity. The genes TGIF1 and HOXD10 are rarely
considered in the pathogenesis of acute kidney injury. Their identification in this study may result in
better understanding of their roles in nephrotoxicity caused by a variety of drugs. Of note, neither
TGIF1 nor HOXD10 were identified in a prior array based study of colistin nephrotoxicity in mice [36].
Since no population of genotyped renal cells exists to correlate with drug-related phenotypes, a
strength of this investigation was the combination of the LCL model with renal tissue and cells to
discover associations important in renal cytotoxicity.
The ultimate goal is to use data such as that presented above to predict patients at risk for
nephrotoxicity. To date, no prior GWAS studies have examined the role of genotype in predicting
toxicity to colistin. Human GWAS studies should be performed; however, these will be fraught with at
least one major obstacle: phenotype selection. In practice, clinicians still use creatinine as a late marker
of acute kidney injury. This marker is burdened by confounders, and nephrotoxicity may prove one
of multiple contributors to an episode of acute kidney injury. As new, more sensitive, biomarkers
of acute kidney injury reach clinical practice, this difficulty may be attenuated. Despite remarkable
differences in the IC50 of LCLs and renal cells to colistin, the genes and proteins identified in LCLs still
resulted in alterations in renal cell sensitivity to colistin. Further, the clean phenotype of cytotoxicity
allowed a small number of cell lines to be used to obtain important genetic information. Prospective
pharmacogenomic implementation initiatives are underway [55,56]. Often, array platforms are used
to screen a moderate number of variants important in drug dosing [57]. Future investigations could
include the screening of chr18:3417240 in patients receiving colistin in order to improve the clinical
validity of this SNP in predicting nephrotoxicity.
In conclusion, we present a comprehensive genome-wide association study of colistin mediated
susceptibility. Through this investigation, we identified a SNP, chr18:3417240 strongly associated with
colistin cytotoxicity. With additional validation, this SNP may serve as a marker for susceptibility to
colistin in the future. Its host gene, TGIF1, and an associated protein HOXD10 were found to contribute
to colistin cytotoxicity in renal proximal tubular cells. Both TGIF1 and HOXD10 are worthy targets for
future investigation of nephrotoxicity in humans.
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4. Materials and Methods
4.1. Cell Lines and Drug
Lymphoblastoid cell lines were cultured in RPMI 1640 media with 15% bovine growth serum
(Hyclone, Logan, UT, USA) and 3.7 mM-glutamine. Cell lines were diluted three times per week to a
concentration of 300,000–350,000 cells/mL and maintained in a 37 ◦ C, 5% CO2 humidified incubator.
Media and components were purchased from Cellgro (Herndon, VA, USA). HapMap LCLs were
purchased from Coriell Institute for Medical Research (Camden, NJ, USA). The 68 LCLs of Yoruban
ancestry (YRI 1 and YRI 3) were used in previous experiments evaluating protein levels [23,39]. Table S4
lists the cell lines.
Normal human proximal tubular kidney cells [35] were maintained in REGM media (Lonza, Basel,
Switzerland) supplemented with 10% fetal bovine serum (HyClone). Normal human proximal tubular
kidney cells were diluted to 20%–30% confluency three times a week and maintained at 37 ◦ C in 95%
humidified atmosphere with 5% CO2 .
Colistin sulfate was commercially obtained from Sigma (St. Louis, MO, USA).
4.2. Colistin-Induced Cytotoxicity
HapMap LCLs were phenotyped for cellular sensitivity to colistin using a short-term, colorimetric
growth inhibition assay. Cell lines were maintained at exponential growth phase with ≥85% viability
as determined using the Vi-Cell XR viability analyzer (Beckman Coulter, Fullerton, CA, USA) and
diluted in triplicate at a density of 105 cells/mL in 96-well round-bottom plates (Corning, Inc., Corning,
NY, USA) 24 h prior to drug treatment. Colistin was prepared by dissolving powder in sterile water to
obtain a stock solution of 25 mM with subsequent drug filtration. The drug was dissolved in water
rather than saline or phosphate-buffered saline (PBS) because of its increased stability [58]. The drug
was suspended in media and in turn added to the 96-well plates of each cell line to obtain six final
concentrations of colistin (50, 100, 175, 250, 375 and 500 µM). The range of concentrations was carefully
chosen based on previously published in vitro cytotoxicity data [59,60] and optimized for these cell
lines. Alamar Blue (Life Technologies, Carlsbad, CA, USA) was added 48 h after drug addition and 24 h
before absorbance reading at wavelengths of 570 and 600 nm using the Synergy-HT multi-detection
plate reader (BioTek, Winooski, VT, USA). Percent survival was quantified relative to a control well
without drug addition. Experiments consisted of at least two biological replicates and six technical
replicates. The phenotype chosen for analysis was the IC50 calculated from the survival curve.
Since NHPTK cells are adherent, they were plated at a density of 2 × 104 in 96-well flat-bottom
plates and growth inhibition was measured using the CellTiter-Glo assay (Promega, Madison, WI,
USA). Cytotoxicity curves were measured 24 h, 48 h, and 72 h after drug treatment using a Spectramax
M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) with seven colistin concentrations (50, 100,
150, 200, 250, 375 and 500 µM).
4.3. Genome-Wide Association and Gene Expression Association with Phenotype
Genotype data were obtained from the 1000 Genomes June 2011 phase I low-pass whole genome
SNP genotype release and utilized the GRCh37/hg19. The location and nomenclature of SNPs
in the text were updated for the GRCh38/hg38 assembly. Missing values were imputed from
the 1000 Genomes Project [61–63] as previously described [39]. A list of the cell lines included
in each analysis is provided in Supplementary Table S4. Analyses were performed to identify SNPs
associated with cellular sensitivity to colistin by regressing the number of minor allele copies for
each SNP against log2 -transformed colistin cytotoxicity IC50 values. All SNPs evaluated had a minor
allele frequency ≥5% and were in Hardy–Weinberg equilibrium (p ≥ 0.001). Regression analyses,
including the relationships between colistin IC50 with gene or protein expression, and the relationships
between genetic variables such as SNPs, baseline gene expression, miRNA, or protein expression were
performed in R [64]. Global baseline gene expression levels measured by RNAseq data [38] was used
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as the metric for mRNA expression. Some expression associations were also evaluated by an Illumina
H6 v2 array [42]. Protein expression was measured using microwestern and reverse phase protein
arrays as previously published [39]. A p-value threshold of ≤0.001 was used in the drug GWAS and in
the subsequent analyses for eQTLs and pQTLs.
4.4. Expression Quantittative Trait Loci and Protein Quantittative Trait Loci Enrichment Analysis
Top colistin-associated SNPs (p ≤ 0.001) were tested for enrichment of eQTLs and pQTLs.
A permutation analysis was performed with one thousand random sets of SNPs, generated from
the set of HapMap YRI SNPs, each with matching minor allele frequency distributions as the set of
significantly associated SNPs. For each random set, the number of eQTLs or pQTLs was determined,
yielding a distribution of the expected counts from which an empirical p-value for the enrichment
was calculated by comparing to the observed count [37]. mRNA-independent pQTLs were examined
using regression analysis on protein expression residuals after regression against mRNA levels for the
same gene.
4.5. Animal Studies and Immunohistochemistry
All animal studies were performed as previously reported [36] and approved by the University of
Chicago and Indiana University School of Medicine’s Institutional Animal Care and Use Committee
(protocol 10670, approval date 1-24-14). In brief, animals were administered colistin 8 mg/kg twice
daily for 3 or 15 days and sacrificed with harvest of their kidneys. Paraffin-embedded sections were
stained using an antibody to HOXD10 (200 µg/mL, 1:100 dilution, sc-66926, Santa Cruz, Dallas, TX,
USA) according to the manufacturer’s instructions, including the optional antigen retrieval step. Renal
staining intensity was scored based on total number of pixels per 40× field (n = 4 mice per group, with
10 fields per mouse) as determined by ImageJ 1.49a [65].
4.6. Small Interfering RNA Nucleofection
Normal human proximal tubular kidney cells were diluted to 500,000 cells/mL one day prior
to nucleofection. Cells were nucleofected using the SF Cell Line Amaxa X-system Nucleofector
Kit (Lonza Inc.) and the CA-137 program on Lonza’s Nucleofector Amaxa X-system. Cells were
then centrifuged at 90× g for 10 min at room temperature and resuspended at a concentration of
1,000,000 cells/20 µL in SF/supplement solution (included in SF Kit Lonza Catalog V4SC2096) and
2000 nM final concentration of All Stars Negative Control siRNA (Qiagen, Inc., Valencia, CA, USA) or
a pool of four siRNA constructs for the genes TGIF1, HOXD10 or both mRNAs together (Dharmacon,
Lafayette, CO, USA). Cells were allowed to rest for 10 min prior to the addition of pre-warmed (37 ◦ C
water bath) REGM media and then for another 5 min in the warm REGM media. Cells were then
plated for mRNA harvest or drug treatment. Cells were harvested 24 and 48 h post-nucleofection for
gene or protein expression measurements, respectively.
4.7. Quantitative Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure the levels
of expression of TGIF1 and HOXD10 in NHPTK cells. A total of 1 million cells were pelleted 24 h
after nucleofection, washed in ice-cold PBS, and centrifuged to remove PBS. All pellets were stored
at −80 ◦ C until RNA isolation. Total RNA was extracted using the miRNeasy Plus Mini Kit (Qiagen)
following the manufacturer’s protocol. Subsequently, mRNA was reverse transcribed to cDNA using
the Bio-Rad iScript Reverse Transcription Kit (Bio-Rad, Hercules, CA, USA). The final concentration
of cDNA was 25 ng/mL. GAPDH was used as an endogenous control using custom made primers
(Life Technologies) and iTaq Universal SYBR Green (Bio-Rad) on the Bio-Rad iCycler qRT-PCR system.
Primer sequences are given in Table S5. Total reaction was performed in 20 µL volume, which consisted
of 10 µL SYBR green, 4 µL cDNA, 0.4 µL of each primer (0.4 µM concentration), and 5.2 µL of water. The
thermocycler parameters were 95 ◦ C for 30 s, 40 cycles of 95 ◦ C for 15 s, and then a lower temperature
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for 30 s (GAPDH: 60 ◦ C, TGIF1: 50 ◦ C, HOXD10: 56 ◦ C), with ramping speeds of 1.6–1.98 ◦ C/s
and a melt curve. The CT threshold and baseline for each experiment were set automatically by the
Bio-Rad software.
The ∆∆CT method was used to obtain the relative expression of each gene for samples treated
with their associated pool of siRNA or scrambled siRNA. Fold change of the siRNA knockdown as
compared to the scramble was determined by the formula fold change = 2∆∆CT . Gene expression for
each condition is given as a percentage of expression relative to the scramble control. Each knockdown
experiment was conducted three or more separate times with the qRT-PCR samples run in triplicate.
Within each cell line, statistical significance was assessed based on an analysis of variance (ANOVA)
between time points.
4.8. Protein Quantitation by Immunoblot in Normal Human Proximal Tubular Kidney Cells
Western immunoblots were performed to measure the level of protein expression of TGIF1
and HOXD10 in NHPTK cells. Approximately 3 million cells were harvested from a petri dish for
each condition (siScramble, siTGIF1, siHOXD10, siTGIF1 + siHOXD10) on five occasions 48 h after
nucleofection. Media was removed and cells were rinsed with PBS. Radioimmunoprecipitation assay
(RIPA) buffer (0.3 mL) with protease inhibitor was added to the monolayer and cells were removed
with a cell scraper 48 h after nucleofection. Cells were centrifuged at 10,000× g for 10 minutes at
4 ◦ C and the supernatant was used in subsequent immunoblotting. Protein concentrations of each
sample were measured using the bicinchoninic acid (BCA) procedure (Pierce Chemical, Rockford,
IL, USA). Samples (20 µg protein) were electrophoresed through a 4%–12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen Nu-PAGE) under reducing conditions.
Proteins were transferred to an Immobilon-P nitrocellulose membrane (Millipore, Bedford, MA, USA)
and blocked for 2 h in 5% w/v milk. Membranes were incubated overnight with rabbit polyclonal
anti-HOXD10 (200 µg/mL, 1:200 dilution) in 5% milk. A secondary goat anti-rabbit HRP antibody
(sc-2004, 1:2000 dilution) was then incubated for 1 h. A protein molecular size ladder control was
run for each membrane with Precision Plus Protein WesternC (Bio-Rad, Hercules, CA, USA). The gel
was developed with ECL prime (GE, Piscataway, NJ, USA) and analyzed in a Bio-Rad ChemiDoc
MP imaging system. An actin-β control was performed for each membrane with mouse anti-actin-β
antibody (sc-47778, 1:250) and goat anti-mouse horseradish peroxidase (HRP; sc-2005, 1:5000). Band
density was assessed with Biorad Image Lab 4.1 software and normalized to actin-β for each lane.
4.9. Drug Treatment after Nucleofection
Normal human proximal tubular kidney cells were plated in triplicate at a density of
2 × 104 cells/mL in 96-well flat-bottom plates and colistin was added 24 h later. Each knockdown
experiment was conducted three or more separate times (at least three biologic replicates and
six technical replicates). Cell survival was measured 24, 48, and 72 h post-drug treatment
using the Cell-Titer Glo assay (Promega, Madison, WI, USA). Relative change in resistance
to colistin was calculated as follows: (SurvivalsiCondition, colistin (µM) / SurvivalsiCondition, control )/
(SurvivalsiScramble, colistin (µM) /SurvivalsiScramble, control ), in which colistin (µM) = colistin treated cells at
a given concentration; Control = vehicle treated cells, siCondition = siRNA experimental knockdown
group, and siScramble = scrambled siRNA control group.
4.10. Small Interfering RNA Statistical Analysis
To assess the size and significance of the effect of siRNA on NHPTK cell survival after colistin
treatment, a linear mixed model used was: survival~siRNA + (1|experiment). The mixed-effects
model was fit using the lmer function from the lme4 package in R version 2.15.2. Significance of the
siRNA term in the model was assessed using a likelihood ratio test.
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